Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
series C
Biotech
Sling reels in $123M to fund oral Tepezza rival through ph. 3
The Michigan-based biotech will use the funds to advance linsitinib as the company began dosing patients in its phase 3 thyroid eye disease study.
Marissa Russo
Sep 16, 2026 7:00am
AusperBio adds $120M series C to push hep B drug through ph. 3
Aug 28, 2026 10:26am
Terremoto takes $108M series C to fuel trials of AKT1 inhibitors
Apr 15, 2026 7:43am
Endogenex nets $50M to develop pulsed-field diabetes procedure
Mar 25, 2026 10:48am
Cognito reaps $105M in funding for its Alzheimer's device
Mar 6, 2026 7:30am
Science closes major $230M series C round
Mar 5, 2026 10:50am
